Physician profile
John Michael Bridges
NPI 1790170520
$2,022.15
in general payments reported to CMS, 2019-2025
14 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Pediatric Rheumatology provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $154 · 2021: $249 · 2022: $471 · 2024: $247 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $534.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $307.96 | 2019-2020 | |
| Amgen INC. | $283.00 | 2019-2025 | Tavneos |
| Sobi, INC | $262.81 | 2020-2025 | |
| Ucb, INC. | $196.50 | 2022-2024 | |
| Janssen Biotech, INC. | $151.99 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $130.77 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $125.00 | 2022 | |
| Janssen Scientific Affairs, LLC | $118.11 | 2021 | |
| Genzyme Corporation | $111.83 | 2022 | |
| Genentech USA, INC. | $99.77 | 2019 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Antares Pharma, INC. | $16.82 | 2019 | |
| Seagen INC. | $12.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bridges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.